Mercer Global Advisors
SNDX icon

Mercer Global Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

Mercer Global Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$404K Sell
18,490
-5,147
-22% -$107K ﹤0.01% 2497
2026
Q1 		$552K Buy
23,637
+5,832
+33% +$127K ﹤0.01% 1915
2025
Q4 		$374K Buy
+17,805
New +$311K ﹤0.01% 2071

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Mercer Global Advisors's SNDX Position: Q2 2026 in Review

Mercer Global Advisors reduced its Syndax Pharmaceuticals (SNDX) stake by 22% in Q2 2026, selling an estimated $107K and leaving 18,490 shares worth $404K. The position accounts for ﹤0.01% of the portfolio, ranked #2497.

Mercer Global Advisors first reported a position in SNDX in Q4 2025 and has held it in 3 quarters since. The position peaked at $552K in Q1 2026. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Mercer Global Advisors held 18,490 shares of Syndax Pharmaceuticals worth $404K as of Q2 2026.
  • Mercer Global Advisors sold 5,147 Syndax Pharmaceuticals shares in Q2 2026, an estimated $107K.
  • Syndax Pharmaceuticals made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #2497 holding.
  • Mercer Global Advisors first reported a position in Syndax Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Mercer Global Advisors's Syndax Pharmaceuticals position peaked at $552K in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.